| Market Cap | $2.57M-96.9% |
| Revenue (ttm) | $20.90M |
| Net Income | -$25.46M |
| EPS | -$1.35 |
| Shares Out | 33.82M |
| PE Ratio | n/a |
| Forward PE | -0.09 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,861,690 |
| Open | $0.08 |
| Previous Close | $0.08 |
| Day's Range | $0.07 - $0.08 |
| 52-Week Range | $0.07 - $2.69 |
| Beta | 6.30 |
| Analysts | none |
| Price Target | $1.93(+2432.89%) |
| Earnings Date | Nov 16, 2026 |
About VVOS
Vivos Therapeutics, Inc. operates as a medical technology and healthcare services company that develops and commercializes treatment modalities for patients with dentofacial abnormalities, obstructive sleep apnea (OSA), and snoring in adults. It offers The Vivos Method, a non-invasive, non-surgical, non-pharmaceutical, multi-disciplinary treatment modality for the treatment of dentofacial abnormalities, OSA, and snoring. The company also offers VivoScore Program, a screening and home sleep test in adults and children. It markets and sells its appliances, and related treatments and services to licensed professionals, primarily general dentists in the United States and Canada. The company was formerly known as Vivos BioTechnologies, Inc. and changed its name to Vivos Therapeutics, Inc. in March 2018. The company was founded in 2016 and is based in Littleton, Colorado.
What Are Insiders Doing?
View the trades behind this meter — each links to its SEC Form 4 →
Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.
$VVOS stock is featured in our Insider Trades datasets.
→ All Stock ListsRecently reported changes in VVOS holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by VVOS's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
VVOS Estimated quarterly lobbying spending
Source: U.S. Senate LDA
U.S. Patents
New VVOS patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to VVOS from public contracts
Source: USAspending.gov
Bull Case vs Bear Case
AI-generated from VVOS’s recent data — informational, not investment advice
What’s Behind the Score
News check: Q3 revenue beat and operational updates suggest positive near-term execution, though loss reported indicates profitability challenges ahead.
